

### ABSTRACT OF THE DISCLOSURE

Compounds of formula (I) in which  $R^1$  =  $C_{1-6}$  alkyl, optionally halosubstituted;  $R^2$  = H,  $C_{1-4}$  alkyl, optionally halosubstituted or replaced by halogen;  $R^3$  =  $C_{2-4}$  alkyl, optionally halosubstituted;  $R^4$  =  $SO_2NR^5R^6$ ,  $CO_2R^7$  or halogen,  $C_{2-4}$  alkenyl; optionally substituted with  $NR^5R^6$ ,  $SONR^5R^6$ ,  $CONR^5R^6$ ,  $CO^2R^7$  or halogen,  $C_{2-4}$  alkanoyl, optionally substituted with  $NR^5R^6$ ,  $SONR^5R^6$ ,  $CONR^5R^6$ ,  $CO_2R^7$  or halogen;  $R^5$  and  $R^6$  = independently H or  $C^{1-4}$  alkyl, or, together with the N atom to which they are attached, a pyrrolidino, piperidino, morpholino, 4-( $NR^8$ )-1-piperazinyl or 1-imidazolyl ring optionally substituted with one or two  $C_{1-4}$  alkyl groups;  $R^7$  = H,  $C^{1-4}$  alkyl, optionally fluorosubstituted, and  $R^8$  = H,  $C^{1-3}$  alkyl or hydroxyalkyl with 1 – 4 C atoms, or the pharmaceutically acceptable salts thereof are useful for the chemotherapeutic treatment of neuropathies.